Dose Equals Duration — The Principle That Predicts How Long a Neurotoxin Complication Will Last

The patient is sitting in front of you with one brow sitting lower than the other, or a smile that has gone flat on one side, and the only question she actually wants answered is how long this is going to last. Neurotoxin complication duration is not a mystery you have to shrug at. There is a principle that gives you a defensible forecast, and Dr. Chris Croley teaches it in one line: dose equals duration. The more units that reach a given muscle, the longer that muscle stays weak. That single relationship is the backbone of prognosis in neurotoxin complication management — and it is a very different job from planning a treatment.

This resource is about prognosis only. It is not a dosing guide and it is not a correction protocol. It answers one question: given what you know about how the toxin got where it went, what can you reasonably tell the patient about time?

The principle, stated properly

Botulinum toxin does not have a fixed duration. Its clinical duration in any individual muscle is a function of how much active toxin reaches the nerve terminals in that muscle and how long neuromuscular transmission stays blocked before functional recovery occurs. More toxin at the terminal means a longer block. Less toxin means a shorter one.

That is the whole mechanism behind "dose equals duration," and it is why the same vial, drawn on the same day, produces a twelve-week effect in the muscle you aimed at and a four-week effect in the muscle next door. Nothing about the toxin changed. The dose that arrived changed.

Two clinical consequences follow immediately, and they are the reason this principle matters far more for prognosis than for planning:

1. The muscle you intended to treat received the full dose. It will run the full expected duration.
2. The muscle affected by diffusion received a fraction of a dose. It will recover sooner — often substantially sooner.

Dr. Croley puts the second point plainly: "more often than not, the side that was inadvertently treated will wear off in a shorter period of time than the expected duration of your entire neurotoxin."

Why this is true of nearly every neurotoxin complication

The reason dose-equals-duration works so reliably as a prognostic tool is that the underlying error in most complications is not the error clinicians assume it is.

"Usually when we have a complication it's not because I directly injected the wrong muscle," Dr. Croley teaches. "Most of us inject the correct muscles, but often they're very close to other muscles that we may not want to inject. And so occasionally some of the dose that we give leaks over, diffuses over, affects that muscle that we didn't want to treat."

Read that carefully, because the prognosis depends entirely on it. If you had genuinely placed your needle in the wrong muscle and deposited the full aliquot there, that muscle would be weak for the full duration — twelve weeks or more. That is a bad outcome with a long horizon.

But that is not what usually happens. What usually happens is that a correctly placed dose spreads. The unintended muscle receives a share of the dose, not the dose. And because dose equals duration, a share of the dose buys a share of the duration.

This is the single most useful thing you can hold onto at the chairside when a complication presents: the complication is, in most cases, on a shorter clock than the treatment that caused it.

What you cannot say

Here is where clinicians get themselves into trouble, and where Dr. Croley's intellectual honesty is the actual teaching point.

"There's no way we know," he says. "We don't have magic glasses. We don't know exactly how much toxin affected that muscle. So it's impossible for me to tell the patient this will only be two weeks or only be six weeks."

You cannot quantify a diffusion dose. There is no assay at the chairside, no imaging that shows you how many units crossed into the zygomaticus or the depressor labii inferioris. You know the direction of the effect and you know the direction of the timeline. You do not know the number.

Any clinician who tells a patient "this will be gone in three weeks" is making a number up. When the number is wrong — and it will sometimes be wrong — you have converted a manageable clinical event into a trust failure. The patient will not remember that the asymmetry resolved. She will remember that you told her three weeks.

Say the shape of the answer, not the number:

"The muscle I treated on purpose got the full dose, so that effect will run its normal course. The muscle that was affected by spread got much less than a full dose, and that effect should resolve sooner. I can't tell you the exact week, because there's no way to measure how much reached that muscle. What I can tell you is the order in which things will come back."

That sentence is honest, it is clinically accurate, and it gives the patient something real to hold onto: a sequence, not a date.

Applying it: a three-question prognostic read

When a complication presents, work through three questions before you say anything about time.

1. Was this a diffusion effect or a placement effect? Look at the geometry. If the affected muscle is immediately adjacent to your injection point, within a centimetre or two, and the effect is partial rather than complete, you are almost certainly looking at diffusion — and the shorter clock applies. If the affected muscle is remote from anything you injected, or the weakness is as complete as the intended effect, reconsider whether the needle was where you thought it was. That is a longer clock.

2. How complete is the weakness? Partial weakness is a dose signal. A muscle that still moves, just less than its partner, received a small fraction of a dose and will recover comparatively quickly. A muscle with no movement at all received enough toxin to approach a full block, and you should forecast conservatively.

3. What dose did the intended muscle receive? Diffusion dose scales with the dose you placed. A complication arising next to a 20-unit masseter is a different prognostic animal from one arising next to a 4-unit depressor anguli oris. The bigger the deposit, the bigger the spillover, and the longer the spillover lasts. This is also the reason Dr. Croley's standing instruction — be conservative, you can always add more — is a prognostic instruction as much as an aesthetic one.

Where the principle breaks down

Dose equals duration is a strong relationship, not a law, and the honest version of this teaching includes its limits.

• Muscle mass changes the arithmetic. A given number of units distributed across a large, dense muscle produces a weaker and shorter effect than the same units in a small, thin one. A partial dose landing in a thin patient's zygomaticus minor may behave more like a full dose than the unit count suggests.
• Individual duration varies. Some patients metabolise their toxin effect fast and some run long, and a patient who reliably reports fourteen weeks from a standard glabellar treatment will likely run long on the complication too.
• Product is a variable. Dysport, Xeomin, Jeuveau and Daxxify are not unit-interchangeable with onabotulinumtoxinA or with each other, and their duration profiles are not identical. A prognosis built on your experience with one product does not transfer cleanly to another.
• Repeat exposure muddies the picture. If the patient has had a treatment layered on top of a treatment that had not fully worn off, you are forecasting the resolution of two overlapping doses, not one.

None of these invalidate the principle. They are reasons to widen your stated range and narrow your confidence — which is the correct response to uncertainty in any case.

What this changes at the chairside

Prognosis is not an academic exercise. It drives three decisions on the day.

It sets the default to watchful waiting. If the complication is on a shorter clock than the treatment, then in many cases the correct management is to let it resolve. Every corrective injection you place is another dose with its own duration, and correcting a four-week problem with a twelve-week intervention is a net loss for the patient. The threshold for intervening should be high, and it should be driven by the patient's functional and social needs rather than by your discomfort.

It reframes the consultation. The patient wants a date. You are giving her a sequence and a mechanism. Done well, this is reassuring rather than evasive, because you are demonstrating that you know exactly what happened and why.

It shapes your documentation. Record which muscle you intended to treat, the dose placed, the muscle you believe was affected by spread, and your reasoning for the expected recovery order. If the patient returns at week six unhappy, that note is the difference between a clinician who anticipated the course and one who is improvising.

For an applied view of how unit selection interacts with duration in a routinely treated region, the frontalis dosing discussion covers the on-label side of the same relationship, and the facial mapping reference is a useful orientation to the adjacency problems that create diffusion complications in the first place.

The honest summary

Dose equals duration tells you the direction of the answer with high confidence and the magnitude with none. That is genuinely useful, because direction is what determines management. The complication is usually shorter-lived than the treatment. That means waiting is usually right, intervention should be conservative, and your job in the room is to explain a sequence rather than promise a date.

These figures and this approach reflect Dr. Chris Croley's clinical practice as taught in Empire Medical Training's hands-on curriculum. Technique is learned under supervision; this article is educational and is not a substitute for training.

Complication reasoning of this kind rests on anatomy — on knowing which muscle sits beside which, at what depth, and how far a deposit can travel before it matters. That foundation is built in Empire's Complete Botox Training and taken further in Anatomical Based Aesthetics Training.

Related guides in this cluster

Part of Neurotoxin Reconstitution and Dosing.

Clinical GuideOn-Label Reconstitution Across the US Neurotoxins — A Reference Table for InjectorsA complete on-label neurotoxin reconstitution chart for Botox, Dysport, Xeomin, Jeuveau and Daxxify — vial sizes, diluent volumes and u Clinical GuideWhy a Unit of Botox Is Not a Unit of DysportBotox units vs Dysport units are not the same measure. Units are defined by each manufacturer's own potency assay — here is why no conv Clinical GuideBacteriostatic vs Preservative-Free Saline — What the Benzyl Alcohol Actually DoesBacteriostatic saline for neurotoxin reconstitution is off-label but well studied. What benzyl alcohol does to injection pain, potency